{"product_id":"urogenital-imaging-9780470510896","title":"Urogenital Imaging","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cul\u003e \u003cli\u003eOrganised according to presenting signs, with discussion of appropriate investigations\u003c\/li\u003e \u003cli\u003eOutlines strengths and weaknesses of different imaging modalities and discusses appropriate choice of technique in each instance\u003c\/li\u003e \u003cli\u003eReviews differential diagnoses and corroborative tests\u003c\/li\u003e \u003c\/ul\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eForeword xiii\u003c\/p\u003e \u003cp\u003ePreface xv\u003c\/p\u003e \u003cp\u003eContributors xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Adrenal Imaging 1\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eKhaled M. Elsayes, Isaac R. Francis, Melvyn Korobkin and Gerard M. Doherty \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 1\u003c\/p\u003e \u003cp\u003e1.2 Cushing’s syndrome 2\u003c\/p\u003e \u003cp\u003e1.3 Primary hyperaldosteronism 5\u003c\/p\u003e \u003cp\u003e1.4 Pheochromocytoma 8\u003c\/p\u003e \u003cp\u003e1.5 Adrenal cortical carcinoma 12\u003c\/p\u003e \u003cp\u003e1.6 Adrenal incidentaloma 15\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Retroperitoneal Masses 21\u003c\/b\u003e\u003cbr\u003e\u003ci\u003ePietro Pavlica, Massimo Valentino and Libero Barozzi \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 21\u003c\/p\u003e \u003cp\u003e2.2 Retroperitoneal anatomy 21\u003c\/p\u003e \u003cp\u003e2.3 Pathological conditions 22\u003c\/p\u003e \u003cp\u003e2.4 Primary solid retroperitoneal tumors 22\u003c\/p\u003e \u003cp\u003e2.5 Retroperitoneal lymphoma 27\u003c\/p\u003e \u003cp\u003e2.6 Cystic retroperitoneal masses 30\u003c\/p\u003e \u003cp\u003e2.7 Retroperitoneal metastases 32\u003c\/p\u003e \u003cp\u003e2.8 Retroperitoneal fibrosis (Ormond’s disease) 33\u003c\/p\u003e \u003cp\u003e2.9 Retroperitoneal fluid collections (traumatic and non-traumatic) 35\u003c\/p\u003e \u003cp\u003eReferences 41\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Imaging of Renal Artery Stenosis 43\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eRobert Hartman \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 43\u003c\/p\u003e \u003cp\u003e3.2 Clinical features 43\u003c\/p\u003e \u003cp\u003e3.3 Pathology 45\u003c\/p\u003e \u003cp\u003e3.4 Imaging of suspected renal artery stenosis 45\u003c\/p\u003e \u003cp\u003eReferences 51\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Renal Masses 53\u003c\/b\u003e\u003cbr\u003e\u003ci\u003ePhilip J. Kenney \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 53\u003c\/p\u003e \u003cp\u003e4.2 Symptomatic renal carcinoma 53\u003c\/p\u003e \u003cp\u003e4.3 Incidental renal masses 55\u003c\/p\u003e \u003cp\u003e4.4 Patients with a known cancer (other than RCC) 62\u003c\/p\u003e \u003cp\u003e4.5 Renal mass in patients with symptoms 63\u003c\/p\u003e \u003cp\u003e4.6 Vascular lesions presenting as a renal mass 68\u003c\/p\u003e \u003cp\u003e4.7 Renal mass in patients with cystic disease 72\u003c\/p\u003e \u003cp\u003e4.8 Treatment 73\u003c\/p\u003e \u003cp\u003eReferences 73\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Non-neoplastic Renal Cystic Lesions 75\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eSameh K. Morcos \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 75\u003c\/p\u003e \u003cp\u003e5.2 Classification 75\u003c\/p\u003e \u003cp\u003e5.3 Cystic lesions affecting renal cortex 76\u003c\/p\u003e \u003cp\u003e5.4 Cystic lesions of renal medulla 80\u003c\/p\u003e \u003cp\u003e5.5 Cystic diseases affecting both the cortex and medulla 86\u003c\/p\u003e \u003cp\u003eReferences 97\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Urological and Vascular Complications Post-renal Transplantation 99\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eTarek El-Diasty and Yasser Osman \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 99\u003c\/p\u003e \u003cp\u003e6.2 Vascular complications 99\u003c\/p\u003e \u003cp\u003e6.3 Urological complications 107\u003c\/p\u003e \u003cp\u003e6.4 Ureteric strictures 110\u003c\/p\u003e \u003cp\u003e6.5 Post-transplant lymphocele 113\u003c\/p\u003e \u003cp\u003e6.6 Delayed graft function (DGF) 116\u003c\/p\u003e \u003cp\u003e6.7 Post-transplant bladder malignancy 119\u003c\/p\u003e \u003cp\u003eReferences 120\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Urinary Tract Injuries 121\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eElliott R. Friedman, Stanford M. Goldman and Tung Shu \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 121\u003c\/p\u003e \u003cp\u003e7.2 Renal trauma 121\u003c\/p\u003e \u003cp\u003e7.3 Adrenal trauma 130\u003c\/p\u003e \u003cp\u003e7.4 Ureteral trauma 131\u003c\/p\u003e \u003cp\u003e7.5 Bladder trauma 133\u003c\/p\u003e \u003cp\u003e7.6 Urethral trauma 136\u003c\/p\u003e \u003cp\u003e7.7 Penile and scrotal trauma 142\u003c\/p\u003e \u003cp\u003eReferences 147\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Urinary Tract Infections 149\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eMikael Hellström, Ulf Jodal, Rune Sixt and Eira Stokland \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Symptomatic urinary tract infection in children 149\u003c\/p\u003e \u003cp\u003e8.2 Symptomatic upper urinary tract infection in adults 167\u003c\/p\u003e \u003cp\u003e8.3 Emphysematous pyelonephritis 173\u003c\/p\u003e \u003cp\u003e8.4 Xanthogranulomatous pyelonephritis 174\u003c\/p\u003e \u003cp\u003e8.5 Urinary tract infection in the immunocompromised patient 177\u003c\/p\u003e \u003cp\u003e8.6 Tuberculosis 179\u003c\/p\u003e \u003cp\u003e8.7 Schistosomiasis 183\u003c\/p\u003e \u003cp\u003e8.8 Hydatid disease (echinococcosis) 188\u003c\/p\u003e \u003cp\u003e8.9 Urethritis 191\u003c\/p\u003e \u003cp\u003eReferences 193\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Imaging of the Genitourinary System – Urolithiasis 195\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eSami A Moussa and Paramananthan Mariappan \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 195\u003c\/p\u003e \u003cp\u003e9.2 Pathology 195\u003c\/p\u003e \u003cp\u003e9.3 Clinical features 197\u003c\/p\u003e \u003cp\u003e9.4 Evaluation of patients with suspected urinary stones 198\u003c\/p\u003e \u003cp\u003e9.5 Treatment 198\u003c\/p\u003e \u003cp\u003e9.6 Imaging 199\u003c\/p\u003e \u003cp\u003eReferences 218\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Hematuria 219\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eThomas Bretlau, Kirstine L. Hermann, Jørgen Nordling and Henrik S. Thomsen \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Definition 219\u003c\/p\u003e \u003cp\u003e10.2 Clinical considerations 219\u003c\/p\u003e \u003cp\u003e10.3 Diagnosis of hematuria 220\u003c\/p\u003e \u003cp\u003e10.4 Epidemiology 220\u003c\/p\u003e \u003cp\u003e10.5 Distribution of malignancy in patients with hematuria 223\u003c\/p\u003e \u003cp\u003e10.6 Imaging 223\u003c\/p\u003e \u003cp\u003e10.7 Summary 230\u003c\/p\u003e \u003cp\u003eReferences 234\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Bladder Cancer 235\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eG. Heinz-Peer and C. Kratzik \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 235\u003c\/p\u003e \u003cp\u003e11.2 Clinical features 237\u003c\/p\u003e \u003cp\u003e11.3 Pathology 239\u003c\/p\u003e \u003cp\u003e11.4 Imaging findings 243\u003c\/p\u003e \u003cp\u003e11.5 Treatment planning 253\u003c\/p\u003e \u003cp\u003e11.6 Post-treatment Imaging 254\u003c\/p\u003e \u003cp\u003e11.7 Summary 254\u003c\/p\u003e \u003cp\u003eReferences 255\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Imaging of Urinary Diversion 257\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eSameh Hanna and Hesham Badawy \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 257\u003c\/p\u003e \u003cp\u003e12.2 Indications for urinary diversion 257\u003c\/p\u003e \u003cp\u003e12.3 Types of urinary diversion 257\u003c\/p\u003e \u003cp\u003e12.4 Non-continent cutaneous form of diversion 258\u003c\/p\u003e \u003cp\u003e12.5 Continent cutaneous urinary diversion (Continent Catheterizing Pouches) 258\u003c\/p\u003e \u003cp\u003e12.6 Non-orthotopic continent diversion, relying on the anal sphincter for continence 260\u003c\/p\u003e \u003cp\u003e12.7 Orthotopic form of diversion to the native, intact urethra (neobladder) 261\u003c\/p\u003e \u003cp\u003e12.8 Contraindications to urinary diversion 264\u003c\/p\u003e \u003cp\u003e12.9 Complications of urinary diversions 264\u003c\/p\u003e \u003cp\u003e12.10 The role of radiologist in urinary diversion includes 267\u003c\/p\u003e \u003cp\u003e12.11 Imaging studies 268\u003c\/p\u003e \u003cp\u003e12.12 Imaging of complications 269\u003c\/p\u003e \u003cp\u003e12.13 Summary 271\u003c\/p\u003e \u003cp\u003eReferences 271\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Imaging of the Prostate Gland 273\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eFrançois Cornud \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 273\u003c\/p\u003e \u003cp\u003e13.2 Zonal anatomy and benign prostatic hypertrophy 273\u003c\/p\u003e \u003cp\u003e13.3 Diagnosis of prostate cancer: TRUS features 276\u003c\/p\u003e \u003cp\u003e13.4 Diagnostic of prostate cancer: MRI 284\u003c\/p\u003e \u003cp\u003e13.5 Contrast-enhanced (dynamic) MRI 285\u003c\/p\u003e \u003cp\u003e13.6 Magnetic Resonance Spectroscopic Imaging (MRSI) 290\u003c\/p\u003e \u003cp\u003e13.7 Diffusion-weighted imaging 292\u003c\/p\u003e \u003cp\u003e13.8 Indications of functional MRI 295\u003c\/p\u003e \u003cp\u003e13.9 Extension of prostate cancer 297\u003c\/p\u003e \u003cp\u003e13.10 Local extension by TRUS and TRUS-guided biopsy 297\u003c\/p\u003e \u003cp\u003e13.11 MRI and staging of prostate cancer 298\u003c\/p\u003e \u003cp\u003e13.12 Local staging 299\u003c\/p\u003e \u003cp\u003e13.13 Lymph node metastases: lympho-MRI 304\u003c\/p\u003e \u003cp\u003e13.14 Bone metastases: whole marrow MRI 304\u003c\/p\u003e \u003cp\u003e13.15 Benign disorders of the prostate (BPH excluded) 305\u003c\/p\u003e \u003cp\u003eReferences 321\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Haemospermia 323\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eDrew A. Torigian, Keith N. Van Arsdalen and Parvati Ramchandani \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 323\u003c\/p\u003e \u003cp\u003e14.2 Clinical features 323\u003c\/p\u003e \u003cp\u003e14.3 Pathology 325\u003c\/p\u003e \u003cp\u003e14.4 Imaging findings 325\u003c\/p\u003e \u003cp\u003e14.5 Summary 337\u003c\/p\u003e \u003cp\u003eReferences 337\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Scrotal Masses 339\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eLorenzo E. Derchi and Alchiede Simonato \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 339\u003c\/p\u003e \u003cp\u003e15.2 Clinical features 339\u003c\/p\u003e \u003cp\u003e15.3 Pathology 340\u003c\/p\u003e \u003cp\u003e15.4 Imaging 340\u003c\/p\u003e \u003cp\u003e15.5 Important principles in assessment of scrotal masses 341\u003c\/p\u003e \u003cp\u003e15.6 Important problems in differentiating benign from malignant lesions 345\u003c\/p\u003e \u003cp\u003eReferences 350\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Gynaecological Adnexal Masses 351\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eJohn A. Spencer and Michael J. Weston \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 351\u003c\/p\u003e \u003cp\u003e16.2 Clinical features 351\u003c\/p\u003e \u003cp\u003e16.3 Pathology 352\u003c\/p\u003e \u003cp\u003e16.4 Imaging 354\u003c\/p\u003e \u003cp\u003e16.5 Standard radiographic techniques 355\u003c\/p\u003e \u003cp\u003e16.6 Ultrasound (US) 355\u003c\/p\u003e \u003cp\u003e16.7 MR Imaging (MRI) 366\u003c\/p\u003e \u003cp\u003e16.8 Computed Tomography 373\u003c\/p\u003e \u003cp\u003eReferences 379\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Imaging of Abnormal Uterine Bleeding 381\u003c\/b\u003e\u003cbr\u003e\u003ci\u003ePatricia Noël, Evis Sala and Caroline Reinhold \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Abnormal uterine bleeding 381\u003c\/p\u003e \u003cp\u003e17.2 Adenomyosis 382\u003c\/p\u003e \u003cp\u003e17.3 Leiomyomas 385\u003c\/p\u003e \u003cp\u003e17.4 Endometrial polyp 389\u003c\/p\u003e \u003cp\u003e17.5 Endometrial hyperplasia 391\u003c\/p\u003e \u003cp\u003e17.6 Endometrial carcinoma 394\u003c\/p\u003e \u003cp\u003e17.7 Summary 396\u003c\/p\u003e \u003cp\u003eReferences 397\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Female Pelvic Floor Dysfunction 399\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eRania Farouk El Sayed \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Introduction 399\u003c\/p\u003e \u003cp\u003e18.2 Anatomical considerations 399\u003c\/p\u003e \u003cp\u003e18.3 Pathophysiology of pelvic floor dysfunction 401\u003c\/p\u003e \u003cp\u003e18.4 Clinical features 401\u003c\/p\u003e \u003cp\u003e18.5 Imaging of pelvic floor dysfunction 404\u003c\/p\u003e \u003cp\u003e18.6 Magnetic resonance imaging (MRI) 407\u003c\/p\u003e \u003cp\u003eReferences 413\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Imaging of female infertility 415\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eAhmed-Emad Mahfouz and Hanan Sherif \u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19.1 Introduction 415\u003c\/p\u003e \u003cp\u003e19.2 Polycystic ovary syndrome 415\u003c\/p\u003e \u003cp\u003e19.3 Abnormalities of the fallopian tubes (Hydrosalpinx\/Hematosalpinx, tubal block) 418\u003c\/p\u003e \u003cp\u003e19.4 Fibroids 421\u003c\/p\u003e \u003cp\u003e19.5 Adenomyosis 423\u003c\/p\u003e \u003cp\u003e19.6 Developmental anomalies of the uterus 424\u003c\/p\u003e \u003cp\u003e19.7 Endometriosis 429\u003c\/p\u003e \u003cp\u003e19.8 Imaging 430\u003c\/p\u003e \u003cp\u003eIndex 431\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49402348896599,"sku":"9780470510896","price":132.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470510896.jpg?v=1730480139","url":"https:\/\/bookcurl.com\/products\/urogenital-imaging-9780470510896","provider":"Book Curl","version":"1.0","type":"link"}